Skip to main content
. 2021 Aug 10;11:16176. doi: 10.1038/s41598-021-95508-3

Table 3.

Previous literature about RFCA for SVT in patients with pulmonary hypertension.

Author ESC/ERS PH Clinical group Mean PA pressure (mmHg) Target SVT Success rate Complications
Tongers et al.5 1, 4 (n = unknown) 50 ± 10 AVNRT: 3 100% (3/3) 0% (0/8)
AFL: 5 100% (5/5)
Bradfield et al.6 1 (n = 11), 99 ± 35 AFL: 12 86% (12/14) 14% (2/14)
4 (n = 1) (systolic PA) Right heart failure: 1
Death: 1
Showkathali et al.16 1 (n = 11), 54.5 ± 11.1 AFL: 22 100% (22/22) 0% (0/22)
4 (n = 11)
Luesebrink et al.17 1 (n = 3), 2 (n = 32), 4 (n = 3) 36.3 ± 13.5 AFL 100% (38/38) 0% (0/38)
Bandorski et al. 20) 1 (n = 14), 2 (n = 23), 3 (n = 4), 4 (n = 8), 5 (n = 2), other (n = 4) Unknown AFL: 14 86% (12/14) Unknown
AT: 11 18% (2/11)
IART: 2 100% (2/2)
AVNRT: 4 100% (4/4)

AFL: common atrial flutter, AT: atrial tachycardia, AVNRT: atrioventricular nodal reentrant tachycardia, ERS: European Respiratory Society, ESC: European Society of Cardiology, IART: intra-atrial reentrant tachycardia, PA: pulmonary arterial, PH: pulmonary hypertension, RFCA: radiofrequency catheter ablation, SD: standard deviation, SVT: supraventricular tachycardia.